Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You know...
You might be better off publishing your opinions on www.WGAS.com!!
“Now that, I say that’s no way for a kid to be wastin’ his time, readin’ that long-haired gobbledegook”
Maybe we could just get 1 approval to start....
Wow, even bigger words on this one. That patent will be worth $20 Billion Alone. In thrilled psti lives in a vacuum where nobody can see how smart they are!
They even control the alternate universe where everything they touch turns to gold. Sssshhhhh. Don't say a word.
Poetic prose
"I keep pitchin' 'em and you keep missin' em'"
Common sense is as rare as genius.
Bucket shop?
Tremendous trading volume today... Can't tell if it's all that consolidation, the controller is working overtime or its a big run by investors who see all the POTENTIAL.....
Cluck, cluck
FDApproved will post anything to bury factual posts. Her forecasting ability is worse than the weather woman.
Finally... sensibility over salacious slobbering. Thanks Saud
The Sosei deal will happen before CLI indication
2020 read the 10K
Nope... Now that they have finally gotten the right primary endpoint, Reductions in Amputations, it will take the full 2 years of follow up to get that indication.
That's the agreement wiyh the FDA. In Exchange due the small sample size... Look it up!
2020 earliest.
10Q says 2020
Wilmington flood waters can't make this float.
"set up to commercialize in Japan"
2 years ago.
That's odd.
How's this one working out?
Still have not seen a single mention of this opportunity for patients and psti, after it was boasted about at granting...
Sad on both accounts
Still, very good, unanswered questions.
Would be tremendous case reports for the 'pending sale' conspiracy theorists.
This... worth reading again.
Key super secret strategy going into motion...
PSTI Leadership is suppressing the stock price so the company can be sold at the lowest possible price. SSSSSHHHHHHHHHHHhhh
FDApproved
Monday, 09/17/18 06:35:53 PM
Re: None
0
Post # of 15652
This Stock Is Being Suppressed For A Reason. I Believe It Will Be Quite Evident Why...When The News Breaks ! I'm Patiently Waiting For An October Surprise !
The way psti leadership uses the ATM, gives ATM a whole new meaning... It's their personal ATM. IMO
"As of June 30, 2018, we had sold 3,599,408 shares of common stock at an average price of $1.43 per share. " - Sept. 10K
Why would Anyone believe that psti wouldn't do the EXACT same thing IF we ever make it back to $1.43 again? They have clearly stated they have to raise more money in the SHORT term. They are now the biggest SHORT to compete with, and they think $1.43 is a good return on the stock. Don't over think this TA silliness. The 'Controller' can go on vacation. ha.
Will never happen, the CONTROLLER will keep them independent!
zzaatt
Tuesday, 09/11/18 01:31:17 PM
Re: SKTrader1 post# 80754
0
Post # of 81412
Quote:
Zzzalt/blue/etal......my advice is per what the market saying and what logic says
The "market" says nothing, it's each individual interpreting data (and logic is not applicable, as evidenced by your posts, including this one).
Your narrative is the most pessimistic possible, and to support the negativity you list every standard and boringly similar board platitude.
The "logic" is very simple: in my opinion it makes more sense to see if what has been touted as a potentially revolutionary medical advance will be shown to be an effective therapeutic agent or not. You can participate for about a buck a share.
Your "advice" is to sell quickly, my intention is to stick around and possibly buy more. Amgen has also made a bet that NEO is worth developing, until they change their minds it's a good bet.
For those that have been lambasted by you know who for suggesting the 'market' knows and the sp is the market's opinion of value & potential...
zzaatt
Friday, 09/14/18 11:37:31 AM
Re: SKTrader1 post# 81328
0
Post # of 81412
Quote:
Abu the problem is for so long the market came to same reading
Here we go, again, the market is telling SKT what to do. As a general rule, what the market tells you is to buy high and sell low. That's usually the wrong thing to do.
"that is definitely not in your interest!" -zzatt
Zzaatt, do tell.
PS, I've enjoyed your posts on Cafe'Pharma too.
Funny. not really. zzatt continues with the 'threat' theory, when zzatt makes threats of its own as previously posted.
The taunting here is strikingly diagnosable.
Many thanks, Jackie!
"Maybe Spidey can read Auto's posts and give us a summary of the important points. Perhaps minus the "big words". "
Actually, he's tried in the past and failed. Feel free to look back at past posts re: Neupogen. Then go to the advancement of R18 discussions and UNSCIENTIFIC comparisons and claims of efficacy and the safety in chimps being directly applied to human beings.
About as UNSCIENTIFIC as you can get. But, being a pharma rep that stays home from work and posts, I'm not surprised you value the pharmacy tech's opining.
"Even So." -FDApproved
Jackie, Thank you telling me I was right. I would appreciate a public apology & retraction of your earlier public accusation of lying.
PS, don't forget to include your IMO, when making leaps with the data, otherwise, well, you know the law.
"There is good information there, but much of it is standard boilerplate legalese. Only very naive investors will take it (or "Eich"s "interpretation" of it) seriously. It's lawyerly mendacity at its finest (or ugliest)."
More Chicken-hawking... look back at zzaatt's postings that were followed by allo's, schooling for zzaat about 'boiler plate' language. This is so funny, i'm contacting Warner Bros. about a copyright infringement.
Ouch. At PSTI, TRUTH is as rare as genius! IMHO.
The fact that there is no
'poison pill' in the 10K would also lead one to believe that the intent is to sell vs. partner or go-it-alone. This is a HUHGE departure from what has been espoused from leadership & the cheerleader du jour here at ihub.
Sorry...but,
From the 10K
Pluristem Therapeutics, Inc. 10-K Sep. 7, 2017 4:09 PM ...
https://seekingalpha.com/filing/3691096
The pooled data from the two studies we conducted suggest an AFS rate at one year of 86% in PLX-treated patients versus an AFS ranging between 48% to 66% in patients from placebo arms in other CLI ...
FDApproved
Friday, 09/14/18 11:52:13 PM
Re: None
0
Post # of 15539
Placebo Yielded 66%... Is Absolutely Not True ! That Was The Treatment Arm. Why Do You Say Such False Things ?
"The pooled data from the two studies we conducted suggest an AFS rate at one year of 86% in PLX-treated patients versus an AFS ranging between 48% to 66% in patients from placebo arms in other CLI trials." This is PSTI speak. If its so great, why didn't they make it a primary end point in Phase II? The more data the better.
Sorry, this will never fly as a study or comparable data... you know that allo.
Will have to complete the study as a primary endpoint, was a miss that it wasn't done in the first place. Can't be spun any other way - sorry.
Placebo yielded 66%.... Don't hold your breath that the difference will be statistically significant.
"The primary efficacy endpoint was the change from baseline in maximal walking distance (MWD) at 52 weeks compared to placebo. The key secondary endpoint was the change from baseline in MWD at 52 weeks compared to placebo, in patients treated with 2 doses of PLX-PAD originating from different placentas (Pluristem’s proprietary Bio-Therapeutic approach).
HMMMM. Nowhere does it look at the REDUCTION of amputations (BLOCKBUSTER) - That has to be the miss of the century in study design!
Other endpoints included risk of revascularization and other hemodynamic and clinical outcome measures.
Read the MD comments... an 'option' not a 'breakthrough'
Even Zami, given the platform to be bold and claim 'the cure', like his co-ceo, waters it down nicely...
“These results suggest that PLX-PAD cells may be efficacious in the treatment of PAD and could significantly reduce the need for invasive procedures in these patients..."
No wonder we have to make the changes in the PIII. There are billion$ of differences between an 'advance' and a 'breakthrough' in therapy!